Orphazyme A/S
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Orphazyme A/S - overview
Established
2009
Location
Copenhagen, -, Denmark
Primary Industry
Biotechnology
About
Orphazyme A/S, headquartered in Copenhagen, Denmark, is a biotechnology company specializing in the development of innovative therapies targeted at rare diseases, focusing on enzyme replacement therapies and protein aggregation disorders. Founded in 2009, Orphazyme A/S operates in the biopharmaceutical sector, concentrating on treatments for rare diseases. The firm has undergone strategic changes, including a significant pivot in its business model and focus on enzyme replacement therapies. The company has raised a total of USD 12.
80 mn through various funding rounds, with its most recent deal being a Trade Sale in November 2017, where it raised DKK 600 million by offering shares on the Nasdaq Copenhagen. Its CEO is Anders Hinsby, who leads the company's initiatives from its headquarters in Copenhagen, Denmark. Orphazyme A/S focuses on developing biopharmaceuticals that target rare diseases, particularly enzyme replacement therapies. The company is engaged in creating therapies that address unmet medical needs in conditions characterized by protein aggregation.
Through its commitment to research and development, Orphazyme aims to bring innovative treatments to market that improve patient outcomes. In 2023, Orphazyme A/S reported zero revenue, with an EBITDA of -USD 3,925,676. 50, reflecting the company’s current financial status as it continues to navigate its strategic pathways in biotechnology. Orphazyme A/S aims to expand its product offerings and enter new markets for its enzyme replacement therapies.
The company plans to leverage recent funding from its Trade Sale in November 2017 to support research and development initiatives and enhance its therapeutic pipeline. As it continues to innovate, Orphazyme is positioned to explore geographic expansion into new regions to increase its market presence and drive growth.
Current Investors
Heartcore Capital, Novo Holdings, Novo Holdings
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.orphazyme.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Orphazyme A/S - timeline of key events
Orphazyme A/S - financials
| Fiscal Year Ended | Jun 30, 2010 | Jun 30, 2011 | Jun 30, 2012 | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | 36,193,000 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | (100.0%) | - | - | - |
| EBITDA (USD) | (446,181) | (10,016,788) | (18,543,344) | (36,786,457) | (37,211,028) | (36,598,677) | (62,814,000) | (130,415,000) | (230,286,000) | (332,151,000) | (603,334,000) | (615,192,000) | (39,421,000) | - | - | - |
| Operating Income (USD) | (571,181) | (10,016,788) | (18,560,145) | (36,959,113) | (37,717,491) | (37,102,460) | (63,520,000) | (131,042,000) | (231,652,000) | (335,954,000) | (608,534,000) | (633,303,000) | (41,241,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | (1749.8%) | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | (1699.8%) | - | - | - | - |
| NET Income (USD) | (574,404) | (10,012,734) | (16,786,721) | (35,763,084) | (31,468,197) | (31,958,124) | (57,935,000) | (126,204,000) | (229,600,000) | (337,497,000) | (633,246,000) | (626,539,000) | 26,070,000 | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | (1731.1%) | - | - | - | - |
Orphazyme A/S - employee data
Orphazyme A/S - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board member | BM | ||||||
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.